ClinicalTrials.Veeva

Menu

Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)

Bayer logo

Bayer

Status

Completed

Conditions

Contraception

Treatments

Drug: EE30/DRSP (Yasmin, BAY86-5131)
Drug: Any other OC

Study type

Observational

Funder types

Industry

Identifiers

NCT00905684
YA0801 (Other Identifier)
14565

Details and patient eligibility

About

This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC. Patients will be followed up approximately 6 months after initial visit. Selection of Study Population: Women can be enrolled after decision for treatment with Yasmin or any other OC has been made. Physicians should consult the full prescribing information for the respective OC before enrolling patients and familiarize themselves with the safety information in the product package label.

Enrollment

5,446 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Women who have been found eligible for OC use and have newly been prescribed an OC in accordance with the terms of the respective marketing authorization
  • Starter (first-ever user of an OC) and switcher from another OC (incl. women with a history of OC use)

Exclusion criteria

  • The contraindications and warnings of the Summary of Product Characteristics must be followed.

Trial design

5,446 participants in 2 patient groups

Group 1
Treatment:
Drug: EE30/DRSP (Yasmin, BAY86-5131)
Group 2
Treatment:
Drug: Any other OC

Trial contacts and locations

13

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems